<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Nonarteritic anterior ischemic optic neuropathy: Prognosis and treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Nonarteritic anterior ischemic optic neuropathy: Prognosis and treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Nonarteritic anterior ischemic optic neuropathy: Prognosis and treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Madhura Tamhankar, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nicholas J Volpe, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan Trobe, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Janet L Wilterdink, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 22, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ischemic optic neuropathy is the most common acute optic nerve disorder in patients over age 50 years [
         <a href="#rid1">
          1
         </a>
         ]. Ischemic optic neuropathy is generally categorized as anterior (affecting the optic disc) versus posterior (retrobulbar), and as arteritic versus nonarteritic. Anterior involvement is usual with both arteritic and nonarteritic ischemic optic neuropathy.
        </p>
        <p>
         Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common form of ischemic optic neuropathy. It is an idiopathic, ischemic insult of the optic nerve head characterized by acute, monocular, painless visual loss with optic disc swelling.
        </p>
        <p>
         This topic will discuss the prognosis and treatment of NAION. The epidemiology, pathogenesis, etiologies, clinical features, and diagnosis of NAION are discussed separately. Other forms of ischemic optic neuropathy and other optic neuropathies are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5233.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5256.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">
          "Clinical manifestations of giant cell arteritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5244.html" rel="external">
          "Optic neuropathies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Clinical course and visual outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         After the onset of NAION, vision may continue to deteriorate in some patients over the first few days or weeks. In the Ischemic Optic Neuropathy Decompression Trial (IONDT), 207 patients with an initial visual acuity of 20/64 were reevaluated within 30 days; 29 percent of these patients had progressed [
         <a href="#rid2">
          2
         </a>
         ]. Others report that among patients with a broad spectrum of visual loss at presentation, 5 to 11 percent of patients have significant visual acuity worsening over this time period [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         After this initial period of potential visual decline, most patients stabilize. In the IONDT, objective visual improvement was noted in 43 percent of patients with vision worse than 20/60 at baseline. However, recovery of visual fields is less common, and most patients do not experience significant improvement in their vision [
         <a href="#rid3">
          3,5-8
         </a>
         ].
        </p>
        <p>
         No specific demographic factor or comorbidity (eg, age, sex, diabetes, hypertension) has been associated with visual outcome [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Disc edema typically resolves over two to three months and is followed by optic disc pallor [
         <a href="#rid9">
          9
         </a>
         ]. At six months, the disc appears pale, usually in a diffuse, but sometimes sectoral, pattern [
         <a href="#rid10">
          10
         </a>
         ]. In contrast to patients with giant cell arteritis, patients with NAION do not develop clinically evident optic nerve cupping [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p>
         Continued progression after the first few weeks is unusual; progressive worsening or persistence of disc swelling should prompt investigation into alternative causes of vision loss. (See
         <a class="medical medical_review" href="/z/d/html/5256.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Recurrence
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ipsilateral recurrence
         </strong>
         – Recurrence of NAION in the affected eye is not common; studies report a less than 6 percent same-eye recurrence rate at two years, which may increase to as high as 7.6 percent at three years [
         <a href="#rid1">
          1,13,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contralateral events
         </strong>
         – The risk of NAION in the fellow eye was traditionally believed to be quite high, but prospective studies have found it to be lower than previously thought, with an estimated five-year cumulative incidence of 12 to 19 percent [
         <a href="#rid15">
          15,16
         </a>
         ]. In the IONDT, 418 patients with NAION were prospectively evaluated [
         <a href="#rid16">
          16
         </a>
         ]. At baseline, 21 percent had a history or clinical evidence of NAION in the fellow eye. After a median follow-up of five years, 15 percent of patients developed NAION in the other eye, with a median interval between events of 1.2 years (range 16 days to 6 years).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Diabetes and worse baseline visual acuity in the affected eye have been identified as risk factors for recurrence, but older age, sex, hypertension, anemia, migraine, and smoking have not [
         <a href="#rid16">
          16,17
         </a>
         ]. Patients with diabetes are also more likely to have second-eye involvement at baseline [
         <a href="#rid18">
          18
         </a>
         ]. Younger patients may be at greater risk of recurrence. In a retrospective study of 164 patients less than 50 years in age, 5 percent had evidence of fellow-eye involvement at baseline, 5 percent had simultaneous bilateral involvement, and 32 percent had sequential involvement with a median time between events of 1 year (range 1 week to 14 years) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In many series, the severity of the initial event appears to predict the severity of the subsequent event [
         <a href="#rid1">
          1,2,16,19
         </a>
         ]; however, one-third of patients will have a greater than six-line difference in visual acuities between affected eyes, making an initial mild event not entirely reassuring [
         <a href="#rid17">
          17,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Mortality and other vascular events
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whether NAION indicates a patient at increased risk for cardiac and cerebrovascular event is uncertain. Some studies have not found an increased risk following NAION [
         <a href="#rid21">
          21-24
         </a>
         ]. However, others have reported an increased risk of stroke and myocardial infarction [
         <a href="#rid25">
          25,26
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a large prospective series of 406 patients, a higher cerebrovascular and cardiovascular risk after NAION was reported, although an adjustment for diabetes and hypertension as independent cerebrovascular risk factors was not made [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A more recent study of 97 patients with NAION found a similar incidence of cerebrovascular and coronary ischemic events following NAION compared with risk factor- and age-matched controls in the Framingham and United Kingdom Prospective Diabetes Study database [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no therapy proven to ameliorate the degree of visual impairment in NAION [
         <a href="#rid1">
          1,27,28
         </a>
         ].
        </p>
        <p>
         Novel therapies for NAION are being developed. While some studies suggest a potential vision benefit, none have been confirmed in randomized trials. Thus, such treatments are considered investigational. (See
         <a class="local">
          'Other investigational treatments'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Blood pressure management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who develop NAION in the setting of severe systemic hypotension may benefit from prompt efforts to reverse hypotension, according to uncontrolled observations [
         <a href="#rid29">
          29,30
         </a>
         ]. If this has occurred in the setting of acute blood loss, blood transfusion is advised.
        </p>
        <p>
         Patients with acutely elevated blood pressure should have their blood pressure lowered incrementally rather than abruptly, as this has been described as precipitating NAION in at least one case report [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1309679907">
         <span class="h2">
          Acute medical treatments with uncertain or no benefit
         </span>
        </p>
        <p class="headingAnchor" id="H3593804662">
         <span class="h3">
          Acute aspirin therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         therapy does not appear to influence visual outcomes of acute NAION. In a retrospective case-control study, 23 patients treated with aspirin before and during the course of NAION were compared with 55 patients with NAION who did not use aspirin [
         <a href="#rid31">
          31
         </a>
         ]. Visual outcomes (visual acuity and mean deviation on automated perimetry) were similar in the two groups.
        </p>
        <p>
         Studies investigating
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy in the secondary prevention of vascular outcomes are discussed separately. (See
         <a class="local">
          'Secondary prevention'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoid therapy is not a recommended treatment in NAION as the evidence supporting its efficacy is limited. However, glucocorticoids are sometimes used in NAION when there is concern that giant cell arteritis has not been excluded and in cases of severe bilateral vision loss, as can occur in the perioperative or dialysis setting, despite the absence of compelling evidence [
         <a href="#rid32">
          32,33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5233.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies", section on 'Perioperative ischemic optic neuropathy'
         </a>
         .)
        </p>
        <p>
         Studies evaluating a potential role of glucocorticoids are of low quality. While some anecdotal reports and nonrandomized studies suggest that glucocorticoids may have some benefit in NAION [
         <a href="#rid34">
          34-37
         </a>
         ], other observational studies have not found that glucocorticoid treatment is efficacious [
         <a href="#rid38">
          38,39
         </a>
         ]. In a meta-analysis of eight mostly nonrandomized studies (720 eyes), glucocorticoid therapy was not associated with a benefit on visual acuity outcomes [
         <a href="#rid40">
          40
         </a>
         ]. Two small randomized trials (38 and 90 patients) did not find a benefit for glucocorticoids on visual outcomes [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p>
         Studies investigating intravitreal glucocorticoid therapy are discussed separately. (See
         <a class="local">
          'Other investigational treatments'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Surgical therapies with uncertain or no benefit
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Optic nerve sheath decompression
         </span>
         <span class="headingEndMark">
          —
         </span>
         In optic nerve sheath decompression surgery (ONDS), two or more slits or a window in the optic nerve sheath are created. This procedure allows cerebrospinal fluid to escape, purportedly reducing the pressure surrounding the optic nerve. Compression of the optic nerve sheath is possibly pathogenic in NAION, and in initial reports, this appeared to be a promising strategy in reducing optic nerve damage in NAION [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         The effectiveness of ONDS was evaluated in the Ischemic Optic Neuropathy Decompression Trial (IONDT) [
         <a href="#rid2">
          2
         </a>
         ]. The trial was stopped early. The initial report of the IONDT described six-month outcomes in 244 patients with NAION with age &gt;50 years and a baseline visual acuity worse than 20/64 [
         <a href="#rid8">
          8
         </a>
         ]. Improved visual acuity by at least three lines occurred in 33 percent of the surgical group compared with 43 percent of controls. Visual acuity worsened by at least three lines in 24 percent of the surgical group compared with 12 percent of controls. These results indicate no benefit and possible harm from surgery. In a follow-up report, outcomes at 24 months were similar in treatment groups; vision improved in 31 percent of the surgery group and in 29 percent of controls, while 20 percent in the surgery and 22 percent in the control group had worsened visual acuity compared with baseline [
         <a href="#rid7">
          7
         </a>
         ]. Adverse effects of surgery included pain, diplopia, and central retinal artery occlusion.
        </p>
        <p>
         The conclusions of IONDT were that ONDS appears to be of no value to most patients with NAION and could potentially cause further visual deterioration [
         <a href="#rid2">
          2,44
         </a>
         ]. An unexpectedly high rate of spontaneous improvement in visual acuity was observed in controls [
         <a href="#rid2">
          2,8
         </a>
         ]. ONDS was associated with a lower rate of improvement; at 3, 6, and 12 months of follow-up, patients receiving surgery had a greater risk of losing three or more lines of vision.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Optic neurotomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         This investigational surgical procedure relaxes the scleral ring surrounding the prelaminar and laminar regions of the optic nerve head, with the goal of reducing constriction and preventing necrosis of underperfused nerve fibers. In one study, seven selected patients with severe vision loss (&lt;20/800) from NAION underwent transvitreal nasal radial optic neurotomy [
         <a href="#rid45">
          45
         </a>
         ]. Six patients had visual improvement. The mean preoperative visual acuity was 20/2400. After a mean 13 weeks following surgery, the mean visual acuity was 20/250, with an average of 10 lines of improvement. In the two patients with sufficient visual acuity for preoperative perimetry, visual fields also significantly improved after surgery.
        </p>
        <p>
         While this report appears somewhat promising, there was no control group for comparison and only a few patients were included. Others are skeptical regarding the potential biomechanical effect of this procedure [
         <a href="#rid46">
          46
         </a>
         ]. Moreover, while serious complications were not reported in this series, surgical manipulation of the optic nerve head has the potential to further damage nerve fibers and blood vessels, potentially causing devastating loss of vision [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Vitrectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In one case series, 16 patients with NAION had findings on optical coherence tomography and ultrasound that were consistent with partial posterior vitreous detachment [
         <a href="#rid48">
          48
         </a>
         ]. The authors postulated that elevation of the optic nerve head from traction of the posterior vitreous may have disrupted the microcirculation and axoplasmic flow, leading to optic nerve edema and visual dysfunction. Surgical release of epipapillary vitreous traction via vitrectomy was performed within one month, with visual acuity improvement noted in 15 patients, 9 of whom had greater than three lines of improvement.
        </p>
        <p>
         This was an uncontrolled case series. The findings need to be independently confirmed before this treatment should be adopted. Other authors have disputed the findings and conclusions of this report [
         <a href="#rid49">
          49-51
         </a>
         ]. However, this study raises the possibility of a role of vitreous traction in the pathogenesis of NAION.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Other investigational treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         Research efforts continue to focus on development of a treatment for NAION. Neuroprotective medications that will help with preventing retinal ganglion cell and axonal loss have been tried in animal models. Neuroprotective and neuroregenerative treatments are being investigated both for acute management and for late-stage recovery.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Citicoline
         </strong>
         – Citicoline is a putative neuroprotective agent that has been evaluated in the treatment of acute cerebral infarction. Preliminary studies in NAION suggest that it may provide modest benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a randomized pilot study, 14 patients with NAION were treated with citicoline 1600 mg per day for 60 days. After 60 and 180 days, these treated patients demonstrated overall improvement in visual acuity compared with baseline, while untreated patients did not [
         <a href="#rid52">
          52
         </a>
         ]. Another randomized study evaluated the efficacy of citicoline prescribed daily for six months in 36 patients who were diagnosed with NAION in the preceding 6 to 12 months [
         <a href="#rid53">
          53
         </a>
         ]. At six- and nine-month evaluations, improvement in visual acuity was noted in treated patients versus nontreated patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Levodopa
         </strong>
         – A potential role for dopamine in the treatment of NAION is based on its putative neuroprotective and neuromodulatory effects in the retina, optic nerve, and/or brain, or its activity as a neurotransmitter in the retina.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a nonrandomized study, 18 patients with acute NAION were treated with a three-week course of levodopa within 45 days of vision loss [
         <a href="#rid54">
          54
         </a>
         ]. Outcomes were compared with 19 untreated controls. At six months, levodopa-treated patients were more likely to have had three lines or greater improvement in visual acuity than controls (77 versus 20 percent). No improvement in visual fields was noted. The statistical analysis and handling of confounding variables in this study have been criticized [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Levodopa has also been studied for its potential to aid visual recovery in patients with chronic NAION. An unblinded but randomized study in 20 patients with NAION of at least six months duration found that a six-week course of levod
         <strong>
          o
         </strong>
         pa treatment was associated with significant improvement in visual acuity but had no effect on field loss or color vision [
         <a href="#rid56">
          56
         </a>
         ]. A similar study, performed in 24 patients with a mean duration of NAION of more than 10 months, found no benefit for levodopa on visual outcomes [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brimonidine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">
          Brimonidine
         </a>
         is an alpha-2 agonist that lowers intraocular pressure and is used in the treatment of glaucoma. There have been promising reports from animal studies suggesting that topical brimonidine may have a neuroprotective effect on retinal ganglion cells and reduce optic nerve injury after ischemia [
         <a href="#rid58">
          58-60
         </a>
         ]. However, a randomized placebo-controlled trial found no therapeutic effect of brimonidine 0.2 percent in 36 patients with acute NAION [
         <a href="#rid61">
          61
         </a>
         ]. Moreover, an open-label study of 14 patients treated with brimonidine suggested a trend for worse visual acuity and fields in treated patients compared with matched controls [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic erythropoietin
         </strong>
         – Erythropoietin has potential neuroprotective effects after ischemic injury. In a prospective nonrandomized study of 113 consecutive patients with acute NAION, patients received either systemic intravenous glucocorticoid combined with recombinant human erythropoietin, systemic corticosteroid alone, or neither [
         <a href="#rid63">
          63
         </a>
         ]. Vision outcomes were similar in all patient groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravitreal agents
         </strong>
         – Intravitreal administration of medications offers the promise of delivering targeted medications directly to the source of pathology. However, this route of administration is not without risks, including a small risk of infectious endophthalmitis, retinal detachment, and traumatic cataract estimated at approximately 0.15 percent [
         <a href="#rid64">
          64
         </a>
         ]. None of the agents discussed below are currently recommended in the treatment of NAION.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Triamcinolone
         </strong>
         – Intravitreal
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         acetonide (IVTA), a glucocorticoid, has been administered to patients with NAION with suggested benefit in small case series [
         <a href="#rid65">
          65-67
         </a>
         ]. In one case, treatment was complicated by increase in intraocular pressure requiring antiglaucoma treatment, a complication that occurs in up to 25 percent of patients when IVTA is administered for other indications [
         <a href="#rid68">
          68,69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A retrospective study compared outcomes in 21 patients with NAION who were given a single intravitreal injection of 4 mg of
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         and 15 nontreated patients; both visual acuity and visual fields were improved at six months in the treated versus the nontreated group [
         <a href="#rid70">
          70
         </a>
         ]. In addition, delay to injection was inversely associated with visual acuity achieved at six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Further study in a large randomized trial is needed to confirm the benefits of this treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anti-vascular endothelial growth factor (VEGF) agents
         </strong>
         – VEGF is a signaling protein that stimulates angiogenesis and increases microvascular permeability. Anti-VEGF agents such as
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="10337" href="/z/d/drug information/10337.html" rel="external">
          ranibizumab
         </a>
         have the potential to reduce vasogenic edema and may play a role in decreasing optic nerve head edema and secondary tissue injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         While at least two case reports describe rapid resolution of vision loss and disc edema in patients with NAION treated with intravitreal
         <a class="drug drug_general" data-topicid="10337" href="/z/d/drug information/10337.html" rel="external">
          ranibizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         [
         <a href="#rid71">
          71,72
         </a>
         ], a small nonrandomized study found that visual outcomes were similar in the 17 patients treated with intravitreal bevacizumab compared with eight patients who were not so treated [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Erythropoietin
         </strong>
         – Erythropoietin has potential neuroprotective and possibly neuroregenerative effects after ischemic injury. In one case series, 31 patients with NAION received unilateral intravitreal erythropoietin injection (2000 units) within one month of onset of NAION [
         <a href="#rid74">
          74
         </a>
         ]. Visual acuity improvement occurred in 61 percent of patients within the first month. Vision continued to improve up to three months and then deteriorated, but remained significantly better than baseline at the last six-month follow-up examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Another study in 16 patients with late-stage optic neuropathy and found no benefit from intravitreal erythropoietin injection [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Granulocyte colony-stimulating factor (G-CSF)
         </strong>
         – G-CSF is a neuroprotective agent evaluated in a prospective interventional case series where 14 eyes of 14 patients with NAION received intravitreal injection of G-CSF within two weeks of the onset [
         <a href="#rid76">
          76
         </a>
         ]. The best-corrected visual acuity improved in the first month following injections but decreased subsequently; the final visual acuity was similar to baseline measurements. Visual field parameters were also not improved. While the drug was found to be safe, the beneficial effect only lasted a month.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          QPI-1007
         </strong>
         –
         <strong>
         </strong>
         QPI-1007 is a chemically modified small interfering RNA targeting the expression of the caspase 2 protein, which accumulates in ischemically injured cells and may contribute to apoptosis [
         <a href="#rid77">
          77
         </a>
         ]. QPI-1007 has been studied in NAION, including in a randomized trial of more than 700 patients with acute NAION. Study results have not yet been published [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fibrinogen/low-density lipoprotein (LDL) apheresis
         </strong>
         – Fibrinogen/LDL apheresis, also known as heparin-induced extracorporeal LDL/fibrinogen precipitation (HELP), removes fibrinogen, total cholesterol, LDLs, and triglycerides from plasma and has shown promise in the treatment of microvascular disorders, including peripheral artery disease and sudden hearing loss [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a small, randomized study of 40 patients with recent-onset NAION, visual outcomes were similar in patients assigned to treatment with HELP and those assigned to hemodilution therapy [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperbaric oxygen
         </strong>
         – While case reports have suggested a possible benefit for hyperbaric oxygen in the treatment of NAION, these findings have not been confirmed in well-designed studies [
         <a href="#rid82">
          82
         </a>
         ]. A nonrandomized study compared hyperbaric oxygen treatment in 20 patients with acute NAION with 27 untreated patients and found no significant difference in visual acuity or visual field outcomes in the groups [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stem cell therapy
         </strong>
         – Stem cell therapy has been reported to improve vision in patients with chronic NAION in uncontrolled case series. Possible mechanisms by which visual improvement may occur include paracrine secretion of proteins and hormones, transfer of mitochondria, release of messenger RNA or other compounds via exosomes or microvesicles, and neuronal transdifferentiation of the stem cells [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ten patients with bilateral visual loss due to sequential NAION underwent autologous bone marrow-derived stem cell (BMSC) therapy within the Stem Cell Ophthalmology Treatment Study (SCOTS) [
         <a href="#rid84">
          84
         </a>
         ]. Average duration of visual loss was 9.8 years, and affected eyes were treated with either retrobulbar, subtenon, and intravenous BMSC therapy or, following vitrectomy, intraoptic nerve, subtenon, and intravenous BMSC therapy. Immediately following therapy, 80 percent of patients experienced improvement in Snellen binocular vision and 20 percent remained stable; in follow-up, 74 percent of eyes treated gained vision and 16 percent remained stable. The authors concluded that meaningful visual improvements were seen in a significant percentage of the patients with NAION.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          RPh201
         </strong>
         – RPh201 is a botanical extract of gum mastic or "Arabic gum" that is believed to have neuroprotective effects [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A preliminary randomized trial evaluated 20 patients with NAION diagnosed six months to three years earlier. After 26 weeks of treatment, visual acuity improved by ≥15 letters in 36 percent of eyes in the active treatment group compared with 12 percent of those who received placebo [
         <a href="#rid85">
          85
         </a>
         ]. Overall, 64 percent of treated patients showed improvement in visual acuity compared with 38 percent in placebo-treated patients. A larger follow-up trial is underway [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SECONDARY PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no known effective therapy proven to prevent NAION in the fellow eye [
         <a href="#rid1">
          1,27
         </a>
         ]. Most patients with NAION are treated with daily
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and risk factor management.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Aspirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         We make recommendations for long-term
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy based upon the individual patient's other risk factors and comorbidities rather than on an episode of NAION, as it is unclear that aspirin is beneficial in regard to prevention of NAION recurrence.
        </p>
        <p>
         Four retrospective studies have evaluated the role of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         in the prevention of NAION in the fellow eye with somewhat mixed results. One case-control and one retrospective study, each involving only a few patients, suggested that aspirin therapy was associated with a reduced risk of fellow-eye involvement [
         <a href="#rid17">
          17,87
         </a>
         ]. However, larger retrospective studies have not found evidence of benefit [
         <a href="#rid15">
          15,16
         </a>
         ]. The largest study compared outcomes in 153 patients who had received aspirin following the development of unilateral NAION and 278 who had not [
         <a href="#rid15">
          15
         </a>
         ]. After five years, the cumulative probability of NAION in the fellow eye was similar in the aspirin and no-aspirin groups (17 and 20 percent, respectively).
        </p>
        <p>
         Although there isn't sufficient evidence to support
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy as secondary prevention in NAION, many patients with NAION will be appropriately treated with aspirin therapy on the basis of comorbid vascular disease and/or their underlying vasculopathic risk factors that independently place them at risk for cardiovascular disease and stroke. (See
         <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">
          "Overview of primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Associated conditions and medications
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypercoagulable conditions
         </strong>
         – Patients found to have an underlying hypercoagulable condition may benefit from anticoagulation, as such treatment may prevent future thromboembolic events [
         <a href="#rid88">
          88
         </a>
         ]. See individual topic reviews regarding specific conditions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phosphodiesterase 5 (PDE-5) inhibitors
         </strong>
         – While the association between NAION and PDE-5 inhibitors is unproven, patients who have suffered an event of NAION should be counseled about potential ocular side effects [
         <a href="#rid89">
          89,90
         </a>
         ]. The US Food and Drug Administration (FDA) has advised patients "to stop use of all PDE-5 inhibitors…and seek medical attention in the event of sudden loss of vision in one or both eyes," and that these medications "should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION" [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The data describing the possible association between NAION and PDE-5 inhibitors are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5233.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies", section on 'Phosphodiesterase-5 inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other implicated medications
         </strong>
         – Patients with NAION who are taking other implicated medications (eg,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , interferon alpha, sympathomimetics) should be counseled about the possible association, and alternatives should be considered if available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The data describing the possible association between NAION and these medications are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5233.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies", section on 'Medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sleep apnea
         </strong>
         – Patients with sleep apnea are likely to benefit from treatment, although in one case series of three patients, treatment of sleep apnea did not appear to prevent NAION [
         <a href="#rid92">
          92
         </a>
         ]. In patients with suspicious history for sleep apnea, formal testing should be recommended and treatment offered when indicated. The possible association between sleep apnea and NAION is described separately. (See
         <a class="medical medical_review" href="/z/d/html/5233.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies", section on 'Sleep apnea syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Vascular risk factor management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medical control of underlying vasculopathic risk factors (eg, hypertension, diabetes, and smoking) is indicated in the primary prevention of cardiovascular disease and stroke; it is not known whether such interventions decrease the risk of NAION recurrence.
        </p>
        <p>
         Patients with acutely elevated blood pressure should have their blood pressure lowered incrementally rather than abruptly, as this has been described as precipitating NAION in at least one case report [
         <a href="#rid29">
          29
         </a>
         ]. Over-aggressive control of systemic arterial hypertension may produce nocturnal hypotension, which is believed to be a risk factor for NAION [
         <a href="#rid93">
          93
         </a>
         ]. Patients should be counseled against taking bedtime antihypertensive agents to minimize the risk of nocturnal hypotension. Morning administration of blood pressure medications should be considered. (See
         <a class="medical medical_review" href="/z/d/html/5233.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies", section on 'Nocturnal hypotension'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          VISUAL REHABILITATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         More than 50 percent of patients with NAION are left with visual acuity less than 20/200 with constricted visual fields. These patients may benefit from visual rehabilitation offered by low-vision services [
         <a href="#rid94">
          94,95
         </a>
         ].
        </p>
        <p>
         We do not recommend to our patients a new modality called vision restoration therapy (VRT), which uses a computer program to stimulate areas of residual vision in patients with visual field defects, and which has been advocated for patients with low vision. A randomized, double-blind pilot trial to evaluate the effects of VRT on the visual function in 10 patients with NAION found a nonsignificant trend toward benefit of visual function [
         <a href="#rid96">
          96
         </a>
         ]. However, VRT remains controversial and unproven, and so far there is very little evidence to support the use of VRT as part of low-vision interventions offered to patients with optic neuropathies.
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical course
         </strong>
         – Patients with acute nonarteritic anterior ischemic optic neuropathy (NAION) have a 5 to 10 percent incidence of significant visual acuity worsening over the first several days to few weeks. In most patients, vision then subsequently stabilizes and rarely improves. (See
         <a class="local">
          'Clinical course and visual outcomes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of recurrence in same or fellow eye
         </strong>
         – Over a period of five years after NAION, patients have a 5 to 7 percent risk of recurrence in the same eye, and a 15 to 19 percent risk of recurrence in the fellow eye. Diabetes and greater severity of NAION in the initially affected eye are risk factors for fellow-eye NAION. (See
         <a class="local">
          'Recurrence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular prognosis
         </strong>
         – Patients with NAION do not appear to have a higher mortality or risk for stroke or cardiovascular disease than would otherwise be expected on the basis of their underlying comorbidities. (See
         <a class="local">
          'Mortality and other vascular events'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute management
         </strong>
         – No treatment for NAION has been shown to improve visual acuity outcomes or reduce the risk of recurrence. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with acutely elevated blood pressure should have their blood pressure lowered incrementally rather than abruptly to avoid the theoretical risk of exacerbating vision loss. (See
         <a class="local">
          'Blood pressure management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Optic nerve sheath decompression surgery (ONDS) is not beneficial and is even potentially harmful to vision. (See
         <a class="local">
          'Optic nerve sheath decompression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary prevention
         </strong>
         – While
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and vascular risk factor management have not been shown to improve visual outcomes or reduce recurrence in patients with NAION, these interventions are appropriate for most patients to reduce their risk of stroke and cardiovascular events based on their comorbid risk factors and vascular disease. (See
         <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">
          "Overview of primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally advise morning administration of blood pressure medications to avoid nocturnal hypotension, which may be a risk factor for recurrence of NAION. (See
         <a class="local">
          'Vascular risk factor management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with unilateral NAION, we suggest discontinuation of implicated medications (phosphodiesterase 5 [PDE-5] inhibitors,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , interferon alpha, sympathomimetics) when possible (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), given the potential for increasing the risk of second-eye involvement. (See
         <a class="local">
          'Associated conditions and medications'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropathies. Curr Opin Neurol 2004; 17:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996; 114:1366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold AC, Hepler RS. Natural history of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 1994; 14:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology 2008; 115:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yee RD, Selky AK, Purvin VA. Outcomes of optic nerve sheath decompression for nonarteritic ischemic optic neuropathy. J Neuroophthalmol 1994; 14:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherer RW, Feldon SE, Levin L, et al. Visual fields at follow-up in the Ischemic Optic Neuropathy Decompression Trial: evaluation of change in pattern defect and severity over time. Ophthalmology 2008; 115:1809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update. Arch Ophthalmol 2000; 118:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. JAMA 1995; 273:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS, Zimmerman MB. Optic disc edema in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2007; 245:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2003; 23:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danesh-Meyer HV, Savino PJ, Sergott RC. The prevalence of cupping in end-stage arteritic and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2001; 108:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS, Jonas JB. Optic disc morphology after arteritic anterior ischemic optic neuropathy. Ophthalmology 2001; 108:1586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS, Podhajsky PA, Zimmerman B. Ipsilateral recurrence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 2001; 132:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preechawat P, Bruce BB, Newman NJ, Biousse V. Anterior ischemic optic neuropathy in patients younger than 50 years. Am J Ophthalmol 2007; 144:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck RW, Hayreh SS, Podhajsky PA, et al. Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997; 123:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman NJ, Scherer R, Langenberg P, et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 2002; 134:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupersmith MJ, Frohman L, Sanderson M, et al. Aspirin reduces the incidence of second eye NAION: a retrospective study. J Neuroophthalmol 1997; 17:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: clinical characteristics in diabetic patients versus nondiabetic patients. Ophthalmology 2008; 115:1818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boone MI, Massry GG, Frankel RA, et al. Visual outcome in bilateral nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1996; 103:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WuDunn D, Zimmerman K, Sadun AA, Feldon SE. Comparison of visual function in fellow eyes after bilateral nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1997; 104:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boghen DR, Glaser JS. Ischaemic optic neuropathy. The clinical profile and history. Brain 1975; 98:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Repka MX, Savino PJ, Schatz NJ, Sergott RC. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol 1983; 96:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salomon O, Huna-Baron R, Kurtz S, et al. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1999; 106:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasanreisoglu M, Robenshtok E, Ezrahi D, Stiebel-Kalish H. Do patients with non-arteritic ischemic optic neuritis have increased risk for cardiovascular and cerebrovascular events? Neuroepidemiology 2013; 40:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guyer DR, Miller NR, Auer CL, Fine SL. The risk of cerebrovascular and cardiovascular disease in patients with anterior ischemic optic neuropathy. Arch Ophthalmol 1985; 103:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 118:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold AC, Levin LA. Treatment of ischemic optic neuropathy. Semin Ophthalmol 2002; 17:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkins EJ, Bruce BB, Newman NJ, Biousse V. Treatment of nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol 2010; 55:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly SE, Gordon KB, Horton JC. Salvage of vision after hypotension-induced ischemic optic neuropathy. Am J Ophthalmol 1994; 117:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens WR, Glazer PA, Kelley SD, et al. Ophthalmic complications after spinal surgery. Spine (Phila Pa 1976) 1997; 22:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Botelho PJ, Johnson LN, Arnold AC. The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1996; 121:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korzets A, Marashek I, Schwartz A, et al. Ischemic optic neuropathy in dialyzed patients: a previously unrecognized manifestation of calcific uremic arteriolopathy. Am J Kidney Dis 2004; 44:e93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basile C, Addabbo G, Montanaro A. Anterior ischemic optic neuropathy and dialysis: role of hypotension and anemia. J Nephrol 2001; 14:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelmayer WC, Eigner M, Berger O, et al. Optic neuropathy in uremia: an interdisciplinary emergency. Am J Kidney Dis 2001; 37:E23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JS, Deputy S, Vives MT, Aviles DH. Sudden blindness in a child with end-stage renal disease. Pediatr Nephrol 2004; 19:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moster ML. Visual loss after coronary artery bypass surgery. Surv Ophthalmol 1998; 42:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 2008; 246:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinori M, Ben-Bassat I, Wasserzug Y, et al. Visual outcome of mega-dose intravenous corticosteroid treatment in non-arteritic anterior ischemic optic neuropathy - retrospective analysis. BMC Ophthalmol 2014; 14:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rebolleda G, Pérez-López M, Casas-Llera P, Muñoz-Negrete FJ. Treatment of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids. Graefes Arch Clin Exp Ophthalmol 2013; 251:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen J, Zhu J, Chen L, et al. Steroids in the treatment of nonarteritic anterior ischemic optic neuropathy: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2019; 98:e17861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxena R, Singh D, Sharma M, et al. Steroids versus No Steroids in Nonarteritic Anterior Ischemic Optic Neuropathy: A Randomized Controlled Trial. Ophthalmology 2018; 125:1623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pakravan M, Sanjari N, Esfandiari H, et al. The effect of high-dose steroids, and normobaric oxygen therapy, on recent onset non-arteritic anterior ischemic optic neuropathy: a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2016; 254:2043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sergott RC, Cohen MS, Bosley TM, Savino PJ. Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy. Arch Ophthalmol 1989; 107:1743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickersin K, Li T. Surgery for nonarteritic anterior ischemic optic neuropathy. Cochrane Database Syst Rev 2015; :CD001538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soheilian M, Koochek A, Yazdani S, Peyman GA. Transvitreal optic neurotomy for nonarteritic anterior ischemic optic neuropathy. Retina 2003; 23:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friberg TR, Smolinski P, Hill S, Kurup SK. Biomechanical assessment of radial optic neurotomy. Ophthalmology 2008; 115:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck AP, Ryan EA, Lou PL, Kroll AJ. Controversies regarding radial optic neurotomy for central retinal vein occlusion. Int Ophthalmol Clin 2005; 45:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modarres M, Sanjari MS, Falavarjani KG. Vitrectomy and release of presumed epipapillary vitreous traction for treatment of nonarteritic anterior ischemic optic neuropathy associated with partial posterior vitreous detachment. Ophthalmology 2007; 114:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee MS, Foroozan R, Kosmorsky GS. Posterior vitreous detachment in AION. Ophthalmology 2009; 116:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soheilian M, Yazdani S. Ischemic optic neuropathy. Ophthalmology 2007; 114:2102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lovelace K, O'Donnell T, Enzenauer RW. Anterior ischemic optic neuropathy. Ophthalmology 2007; 114:2368; author reply 2368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parisi V, Coppola G, Ziccardi L, et al. Cytidine-5'-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur J Neurol 2008; 15:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parisi V, Barbano L, Di Renzo A, et al. Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study. PLoS One 2019; 14:e0220435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson LN, Guy ME, Krohel GB, Madsen RW. Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2000; 107:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck RW. Does Levodopa improve visual function in NAION? Ophthalmology 2000; 107:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson LN, Gould TJ, Krohel GB. Effect of levodopa and carbidopa on recovery of visual function in patients with nonarteritic anterior ischemic optic neuropathy of longer than six months' duration. Am J Ophthalmol 1996; 121:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simsek T, Eryilmaz T, Acaroglu G. Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy. Int J Clin Pract 2005; 59:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler LA, Woldemussie E. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur J Ophthalmol 2001; 11 Suppl 2:S30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen R, Cheng T, Li Y, et al. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 1996; 16:5986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999; 40:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilhelm B, Lüdtke H, Wilhelm H, BRAION Study Group. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol 2006; 244:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fazzone HE, Kupersmith MJ, Leibmann J. Does topical brimonidine tartrate help NAION? Br J Ophthalmol 2003; 87:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pakravan M, Esfandiari H, Hassanpour K, et al. The Effect of Combined Systemic Erythropoietin and Steroid on Non-arteritic Anterior Ischemic Optic Neuropathy: A Prospective Study. Curr Eye Res 2017; 42:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye (Lond) 2008; 22:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaderli B, Avci R, Yucel A, et al. Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2007; 27:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jonas JB, Spandau UH, Harder B, Sauder G. Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2007; 245:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yaman A, Selver OB, Saatci AO, Soylev MF. Intravitreal triamcinolone acetonide injection for acute non-arteritic anterior ischaemic optic neuropathy. Clin Exp Optom 2008; 91:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS. Intravitreal triamcinolone for nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2008; 28:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roth DB, Verma V, Realini T, et al. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology 2009; 116:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radoi C, Garcia T, Brugniart C, et al. Intravitreal triamcinolone injections in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2014; 252:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bajin MS, Selver OB, Taskin O, et al. Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischaemic optic neuropathy. Clin Exp Optom 2011; 94:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett JL, Thomas S, Olson JL, Mandava N. Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. J Neuroophthalmol 2007; 27:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rootman DB, Gill HS, Margolin EA. Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: a prospective trial. Eye (Lond) 2013; 27:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modarres M, Falavarjani KG, Nazari H, et al. Intravitreal erythropoietin injection for the treatment of non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 2011; 95:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acar U, Kucuk B, Sevinc MK, et al. Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human. Int Ophthalmol 2018; 38:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abri Aghdam K, Aghajani A, Ashraf Khorasani M, et al. Intravitreal Injection Of The Granulocyte-Colony Stimulating Factor For The Treatment Of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Pilot Study. Semin Ophthalmol 2021; 36:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS. Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 2020; 104:153.
          </a>
         </li>
         <li class="breakAll">
          Trial NCT02341560. Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). US National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT02341560?term=QPI-1007&amp;draw=2&amp;rank=1 (Accessed on September 17, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suckfüll M, Hearing Loss Study Group. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet 2002; 360:1811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramunni A, Brescia P, Quaranta D, et al. Fibrinogen apheresis in the treatment of peripheral arterial disease. Blood Purif 2007; 25:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas A, Walzl M, Jesenik F, et al. Application of HELP in nonarteritic anterior ischemic optic neuropathy: a prospective, randomized, controlled study. Graefes Arch Clin Exp Ophthalmol 1997; 235:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bojić L, Ivanisević M, Gosović G. Hyperbaric oxygen therapy in two patients with non-arteritic anterior optic neuropathy who did not respond to prednisone. Undersea Hyperb Med 2002; 29:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold AC, Hepler RS, Lieber M, Alexander JM. Hyperbaric oxygen therapy for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1996; 122:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss JN, Levy S, Benes SC. Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of non-arteritic ischemic optic neuropathy (NAION). Stem Cell Investig 2017; 4:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rath EZ, Hazan Z, Adamsky K, et al. Randomized Controlled Phase 2a Study of RPh201 in Previous Nonarteritic Anterior Ischemic Optic Neuropathy. J Neuroophthalmol 2019; 39:291.
          </a>
         </li>
         <li class="breakAll">
          Trial NCT03547206. Efficacy &amp; Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). US National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT03547206?term=RPh201&amp;draw=2&amp;rank=5 (Accessed on July 09, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salomon O, Huna-Baron R, Steinberg DM, et al. Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye (Lond) 1999; 13 ( Pt 3a):357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srinivasan S, Fern A, Watson WH, McColl MD. Reversal of nonarteritic anterior ischemic optic neuropathy associated with coexisting primary antiphospholipid syndrome and Factor V Leiden mutation. Am J Ophthalmol 2001; 131:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases. J Neuroophthalmol 2005; 25:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunningham AV, Smith KH. Anterior ischemic optic neuropathy associated with viagra. J Neuroophthalmol 2001; 21:22.
          </a>
         </li>
         <li class="breakAll">
          Levitra (vardenafil hydrochloride) tablets. US FDA approved product information; Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; August 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behbehani R, Mathews MK, Sergott RC, Savino PJ. Nonarteritic anterior ischemic optic neuropathy in patients with sleep apnea while being treated with continuous positive airway pressure. Am J Ophthalmol 2005; 139:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS. Treatment of IOH and risk of visual complications. Arch Intern Med 2002; 162:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stelmack JA, Tang XC, Reda DJ, et al. Outcomes of the Veterans Affairs Low Vision Intervention Trial (LOVIT). Arch Ophthalmol 2008; 126:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamara R, Potaznick W, Matjucha I. Low vision rehabilitation for a target-shooting marksman with visual field loss and diplopia. Optometry 2008; 79:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung CS, Bruce B, Newman NJ, Biousse V. Visual function in anterior ischemic optic neuropathy: effect of Vision Restoration Therapy--a pilot study. J Neurol Sci 2008; 268:145.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5234 Version 12.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15090874" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Ischemic optic neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8906027" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7951929" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Natural history of nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17698200" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7951930" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Outcomes of optic nerve sheath decompression for nonarteritic ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18486224" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Visual fields at follow-up in the Ischemic Optic Neuropathy Decompression Trial: evaluation of change in pattern defect and severity over time.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10865316" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7844872" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17219123" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Optic disc edema in non-arteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12782932" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pathogenesis of nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11237915" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The prevalence of cupping in end-stage arteritic and nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11535455" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Optic disc morphology after arteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11704035" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Ipsilateral recurrence of nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17854756" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Anterior ischemic optic neuropathy in patients younger than 50 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9186127" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Aspirin therapy in nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12208242" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9427177" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Aspirin reduces the incidence of second eye NAION: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18502511" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nonarteritic anterior ischemic optic neuropathy: clinical characteristics in diabetic patients versus nondiabetic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8764790" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Visual outcome in bilateral nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9022112" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Comparison of visual function in fellow eyes after bilateral nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1218373" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ischaemic optic neuropathy. The clinical profile and history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6624829" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical profile and long-term implications of anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10201595" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23364133" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Do patients with non-arteritic ischemic optic neuritis have increased risk for cardiovascular and cerebrovascular events?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4026642" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The risk of cerebrovascular and cardiovascular disease in patients with anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7977604" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15513455" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment of ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20006051" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Treatment of nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8116753" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Salvage of vision after hypotension-induced ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9201834" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Ophthalmic complications after spinal surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8604744" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15558514" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Ischemic optic neuropathy in dialyzed patients: a previously unrecognized manifestation of calcific uremic arteriolopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11730278" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Anterior ischemic optic neuropathy and dialysis: role of hypotension and anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11228200" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Optic neuropathy in uremia: an interdisciplinary emergency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15052465" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Sudden blindness in a child with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9548574" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Visual loss after coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18404273" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24886579" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Visual outcome of mega-dose intravenous corticosteroid treatment in non-arteritic anterior ischemic optic neuropathy - retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22644095" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Treatment of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31725628" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Steroids in the treatment of nonarteritic anterior ischemic optic neuropathy: A PRISMA-compliant meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29705054" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Steroids versus No Steroids in Nonarteritic Anterior Ischemic Optic Neuropathy: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27510295" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The effect of high-dose steroids, and normobaric oxygen therapy, on recent onset non-arteritic anterior ischemic optic neuropathy: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2597065" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25763979" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Surgery for nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14574257" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Transvitreal optic neurotomy for nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17544511" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Biomechanical assessment of radial optic neurotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16199974" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Controversies regarding radial optic neurotomy for central retinal vein occlusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17270682" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Vitrectomy and release of presumed epipapillary vitreous traction for treatment of nonarteritic anterior ischemic optic neuropathy associated with partial posterior vitreous detachment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19264223" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Posterior vitreous detachment in AION.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17980755" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18054657" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18325025" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cytidine-5'-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31348806" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10711891" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10919877" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Does Levodopa improve visual function in NAION?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8554083" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effect of levodopa and carbidopa on recovery of visual function in patients with nonarteritic anterior ischemic optic neuropathy of longer than six months' duration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15857324" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11592528" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8815881" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9888428" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16151785" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12928304" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Does topical brimonidine tartrate help NAION?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28632028" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The Effect of Combined Systemic Erythropoietin and Steroid on Non-arteritic Anterior Ischemic Optic Neuropathy: A Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18292795" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Short-term complications of intravitreal injections of triamcinolone and bevacizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17895814" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16673138" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18976422" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Intravitreal triamcinolone acetonide injection for acute non-arteritic anterior ischaemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18347467" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Intravitreal triamcinolone for nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19157561" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24178807" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Intravitreal triamcinolone injections in non-arteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21255078" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischaemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17895825" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23370417" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: a prospective trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21131378" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Intravitreal erythropoietin injection for the treatment of non-arteritic anterior ischaemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28527030" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33689586" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Intravitreal Injection Of The Granulocyte-Colony Stimulating Factor For The Treatment Of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31488431" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31488431" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12480357" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17901692" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Fibrinogen apheresis in the treatment of peripheral arterial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9034837" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Application of HELP in nonarteritic anterior ischemic optic neuropathy: a prospective, randomized, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12508973" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Hyperbaric oxygen therapy in two patients with non-arteritic anterior optic neuropathy who did not respond to prednisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8862051" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Hyperbaric oxygen therapy for nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29270420" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of non-arteritic ischemic optic neuropathy (NAION).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31430268" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Randomized Controlled Phase 2a Study of RPh201 in Previous Nonarteritic Anterior Ischemic Optic Neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31430268" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Randomized Controlled Phase 2a Study of RPh201 in Previous Nonarteritic Anterior Ischemic Optic Neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10624433" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11336954" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Reversal of nonarteritic anterior ischemic optic neuropathy associated with coexisting primary antiphospholipid syndrome and Factor V Leiden mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15756125" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11315976" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Anterior ischemic optic neuropathy associated with viagra.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11315976" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Anterior ischemic optic neuropathy associated with viagra.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15767063" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Nonarteritic anterior ischemic optic neuropathy in patients with sleep apnea while being treated with continuous positive airway pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12090892" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Treatment of IOH and risk of visual complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18474769" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Outcomes of the Veterans Affairs Low Vision Intervention Trial (LOVIT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18436163" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Low vision rehabilitation for a target-shooting marksman with visual field loss and diplopia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18207164" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Visual function in anterior ischemic optic neuropathy: effect of Vision Restoration Therapy--a pilot study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
